Alendronate and/or Parathyroid Hormone for Osteoporosis
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
This study looks at the effects of two medications, alendronate and parathyroid hormone, on
bone mass and on bone formation and bone breakdown in women with osteoporosis. We will
randomly select postmenopausal women who have osteoporosis to receive laboratory-produced
human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants
will return to the study center periodically to have their bone mass measured and to give
blood and urine samples for tests of bone formation and breakdown and for other laboratory
tests. Those who complete the study are eligible for one or two 12 month extension studies.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)